Molander, D., Sbirkov, Y., Sarafian, V. 3D bioprinting as an emerging standard for cancer modeling and drug testing. Plovdiv: 2022 559-565,.
Molander, D., Sbirkov, Y., Sarafian, V. 3D bioprinting as an emerging standard for cancer modeling and drug testing. Plovdiv: 2022 559-565,.
Molander, D., Sbirkov, Y., Sarafian, V. (2022) 3D bioprinting as an emerging standard for cancer modeling and drug testing, Plovdiv: 559-565,.
Molander, D., Sbirkov, Y., & Sarafian, V. (2022). 3D bioprinting as an emerging standard for cancer modeling and drug testing. Folia Medica, 64 (4), 559-565.
Molander D, Sbirkov Y, Sarafian V. 3D bioprinting as an emerging standard for cancer modeling and drug testing. Folia Medica. 2022; 64(4): 559-565.
